Circulating Tumor Cells CTCs Prognostic Technologies

Circulating Tumor Cells (CTCs) Prognostic Technologies Market Outlook

The global circulating tumor cells (CTCs) prognostic technologies market is projected to reach approximately USD 6.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 19.7% during the forecast period from 2025 to 2035. The key growth factors contributing to this expansion include the increasing incidence of cancer worldwide, advancements in CTC detection technologies, and heightened awareness regarding early diagnosis and monitoring of cancer treatment. Additionally, the growing preference for non-invasive diagnostic methods over traditional biopsies is driving the demand for CTCs, as they provide critical insights into tumor biology and patient prognosis. The ongoing research and development activities aimed at enhancing the accuracy and efficiency of CTC analysis are also expected to play a significant role in propelling market growth.

Growth Factor of the Market

The growth of the circulating tumor cells (CTCs) prognostic technologies market is primarily influenced by several factors that align with the current trends in cancer treatment and diagnostics. One of the foremost growth factors is the rise in cancer prevalence globally, which has led to an increased demand for effective diagnostic tools. Moreover, the trend towards personalized medicine is gaining traction, with CTCs providing real-time insights into the tumor's dynamics, thus enabling tailored treatment approaches for patients. The technological advancements in CTC detection, including the development of microfluidic devices and next-generation sequencing (NGS) technologies, have significantly enhanced the sensitivity and specificity of CTC analysis. Furthermore, the increasing focus on liquid biopsies is contributing to the market’s expansion, as they are less invasive and more patient-friendly. The growing investments in cancer research from both public and private sectors are also propelling innovations in CTC technologies.

Key Highlights of the Market

• Significant increase in the demand for non-invasive cancer diagnostic solutions.
• Technological advancements boosting CTC detection accuracy.
• High prevalence of cancer driving the need for effective monitoring tools.
• Investment in cancer research fostering innovation in diagnostic technologies.
• Emergence of personalized medicine approaches enhancing treatment outcomes.

By Product Type

CTC Detection Devices:

CTC detection devices are critical components of the circulating tumor cells prognostic technologies market, as they facilitate the identification and isolation of CTCs from blood samples. These devices utilize various methodologies, including microfluidic technologies, filtration methods, and immunoaffinity capture techniques to efficiently separate CTCs from leukocytes and platelets. The growing emphasis on early cancer detection and the need for accurate prognostic information drive the demand for these devices. Moreover, advancements in technology are leading to the development of more sensitive and specific CTC detection devices, further enhancing their usability in clinical settings. The increasing adoption of liquid biopsy techniques in oncology is also contributing significantly to the growth of this segment, as they provide valuable information about tumor heterogeneity and treatment response.

CTC Enrichment Methods:

CTC enrichment methods play a pivotal role in isolating circulating tumor cells from a heterogeneous mixture of blood cells, allowing for subsequent analysis of these critical cancer biomarkers. Techniques such as density gradient centrifugation, size-based separation, and immunomagnetic separation are among the most commonly used methods in this segment. The growing focus on personalized medicine and the need for precise tumor characterization are driving investments in developing more efficient and reliable enrichment techniques. Additionally, innovations in microfluidics and nanotechnology are enhancing the efficiency of CTC enrichment, making it easier for researchers and clinicians to analyze these elusive cells. As the importance of CTCs in understanding metastasis and treatment resistance becomes more recognized, the demand for effective enrichment methods is expected to rise significantly.

CTC Analysis Software:

CTC analysis software is crucial for interpreting data obtained from CTC detection and enrichment methods. This software utilizes advanced algorithms and machine learning techniques to analyze the characteristics of CTCs, providing insights into tumor biology and treatment response. The increasing focus on data-driven decision-making in healthcare is propelling the demand for sophisticated analysis software that can handle large sets of genomic and proteomic data. The integration of artificial intelligence in CTC analysis is further enhancing the capabilities of these software solutions, allowing for more accurate predictions regarding patient prognosis and treatment efficacy. As the complexity of cancer genomics continues to grow, the necessity for advanced analysis software that can provide actionable insights will likely drive significant growth in this segment.

By Application

Cancer Diagnosis:

Cancer diagnosis represents a significant application of circulating tumor cells (CTCs) prognostic technologies, as these cells provide critical information regarding the presence of malignancies in patients. The ability to detect CTCs non-invasively makes it an attractive option compared to traditional biopsy methods, which can be more invasive and painful for patients. This application is increasingly recognized for its potential to facilitate early cancer detection, allowing for timely intervention and improved patient outcomes. Furthermore, the growing awareness of the benefits of liquid biopsies among healthcare providers and patients is contributing to the rising adoption of CTC-based diagnostic methods. With ongoing advancements in CTC isolation and detection technologies, the accuracy and reliability of cancer diagnosis using CTCs will continue to enhance, further driving the demand in this segment.

Treatment Monitoring:

The use of circulating tumor cells (CTCs) in treatment monitoring is gaining traction as it provides real-time insights into a patient’s response to therapy. As cancer treatments become increasingly personalized, the ability to track CTC levels over time can inform clinicians on the effectiveness of specific therapeutic interventions. This application allows for timely adjustments to treatment plans based on the dynamics of CTC presence, potentially leading to better patient outcomes. Moreover, the non-invasive nature of CTC monitoring is particularly appealing, as it reduces the need for repeat biopsies and minimizes patient discomfort. As the healthcare sector increasingly focuses on patient-centered care, the importance of monitoring treatment efficacy using CTCs will continue to grow, thus expanding this segment significantly.

Prognostic Evaluation:

Prognostic evaluation utilizing circulating tumor cells (CTCs) has emerged as a crucial application in oncology, as CTCs can provide insights into the aggressiveness of cancer and potential outcomes for patients. The correlation between CTC count and patient prognosis has been supported by numerous clinical studies, establishing CTCs as significant biomarkers for cancer progression. This application enables clinicians to stratify patients based on risk and tailor treatment approaches accordingly, enhancing the overall management of cancer care. The increasing acceptance of prognostic biomarker testing in routine clinical practice is expected to drive demand for CTC-based prognostic evaluation tools. As more research validates the prognostic value of CTCs, the market for this application is poised for substantial growth, further establishing CTCs as pivotal in cancer prognostication.

By User

Hospitals & Clinics:

Hospitals and clinics represent a primary user segment in the circulating tumor cells (CTCs) prognostic technologies market due to their critical role in cancer diagnosis and treatment. These healthcare facilities are increasingly adopting CTC technologies to improve patient care and outcomes, facilitating the integration of novel diagnostic tools into routine clinical practice. The demand for rapid and accurate cancer diagnostics, along with personalized treatment approaches, is driving hospitals and clinics to invest in CTC detection and monitoring technologies. Additionally, the increasing prevalence of cancer necessitates the availability of effective diagnostic solutions within these healthcare institutions. As hospitals and clinics continue to prioritize patient-centered care and the use of advanced diagnostic methods, the demand for CTC technologies in these settings is expected to grow significantly.

Research Institutes:

Research institutes are vital users of circulating tumor cells (CTCs) prognostic technologies, as they play a crucial role in advancing cancer research and developing innovative therapeutic strategies. These institutions leverage CTC technologies to explore tumor biology, metastatic processes, and treatment resistance mechanisms, contributing to the development of personalized medicine approaches. The increasing funding for cancer research and the push towards precision oncology are driving research institutes to utilize CTCs in their studies. Furthermore, the collaboration between academic and clinical entities is enhancing the translational aspect of research, facilitating the application of CTC findings in clinical settings. As the emphasis on research and innovation continues, the role of research institutes in driving the adoption of CTC technologies will remain significant.

Diagnostic Centers:

Diagnostic centers are critical players in the circulating tumor cells (CTCs) prognostic technologies market, primarily focusing on providing accurate and timely diagnostic services to patients. These centers are increasingly adopting CTC technologies as part of their service offerings, recognizing the importance of non-invasive cancer diagnostics in improving patient care. The growing demand for liquid biopsies and the ability to provide comprehensive cancer monitoring services are driving the adoption of CTC detection and analysis methods in diagnostic centers. Moreover, advancements in CTC technologies are enabling these centers to enhance their diagnostic capabilities, leading to improved test accuracy and reliability. As the market for cancer diagnostics continues to evolve, diagnostic centers will play a pivotal role in the widespread adoption of CTC prognostic technologies.

By Technology

Epithelial Cell Adhesion Molecule (EpCAM)-Based:

The epithelial cell adhesion molecule (EpCAM)-based technology is a widely utilized method for the isolation and detection of circulating tumor cells (CTCs), leveraging the unique characteristics of EpCAM expression on epithelial cells. This method allows for the efficient capture of CTCs from blood samples by using antibodies specifically targeting EpCAM. The significant advantage of EpCAM-based technologies is their ability to enrich CTCs, leading to higher detection rates compared to standard blood tests. The growing focus on targeted therapies and personalized medicine is enhancing the demand for EpCAM-based technologies, as they provide vital information about tumor characteristics and treatment response. Moreover, advancements in EpCAM-based assays are continually improving their sensitivity and specificity, further solidifying their role in oncological diagnostics.

Size-Based:

Size-based separation technology is gaining traction in the circulating tumor cells (CTCs) prognostic technologies market as it offers a non-biased method for isolating CTCs based on their size differences from normal blood cells. This technique utilizes microfluidics and filtration systems to separate CTCs from the bloodstream, capitalizing on the larger size of CTCs compared to leukocytes and other components. The advantage of size-based methods lies in their ability to capture a broader range of tumor cells, including those that may lose epithelial markers, thus enhancing the overall detection rate. As the demand for comprehensive cancer diagnostics grows, size-based technologies are expected to witness increased adoption due to their simplicity and effectiveness in CTC isolation.

Density Gradient Separation:

Density gradient separation is another effective technology utilized in the isolation of circulating tumor cells (CTCs) from blood samples. This method leverages the different densities of blood components to separate CTCs using centrifugation techniques. The density gradient allows for the effective enrichment of CTCs while minimizing the contamination from other cellular components, leading to improved detection accuracy. The growing emphasis on liquid biopsy technologies for cancer diagnosis is driving interest in density gradient separation methods, as they provide a reliable means of isolating CTCs for further analysis. As advancements in this technology continue to emerge, it is expected to become increasingly relevant in clinical and research applications.

Immunocapture:

Immunocapture technology is a prominent method employed in the isolation of circulating tumor cells (CTCs), utilizing antibodies that specifically target tumor-associated antigens. This approach allows for the selective capture of CTCs from blood samples, facilitating their subsequent analysis. The major advantage of immunocapture is its ability to provide high specificity in isolating CTCs while preserving their viability for further studies. As the demand for precision oncology continues to increase, immunocapture methods are playing a crucial role in identifying CTCs and characterizing their molecular profiles. The ongoing development of novel antibodies and capture technologies is expected to enhance the effectiveness of immunocapture, further driving its adoption in both clinical and research settings.

By Epithelial Cell Adhesion Molecule

EpCAM:

The epithelial cell adhesion molecule (EpCAM) is a significant target in the isolation and analysis of circulating tumor cells (CTCs), given its overexpression in various epithelial tumors. Utilizing EpCAM-based techniques allows for the selective capture of CTCs from the bloodstream, facilitating their analysis for prognostic and diagnostic purposes. The advantage of targeting EpCAM lies in its ability to enrich CTC populations, leading to improved detection and characterization of tumor cells. The growing recognition of the role of EpCAM in cancer progression and metastasis is further driving its application in CTC technologies. As advancements in EpCAM-based assays continue to evolve, the potential for enhancing cancer diagnostics and treatment monitoring will likely expand, reinforcing the importance of this adhesion molecule in oncology.

Other Adhesion Molecules:

In addition to EpCAM, other epithelial cell adhesion molecules are being explored in the context of circulating tumor cells (CTCs). These molecules can provide critical information regarding tumor biology and metastatic potential. The utilization of multiple adhesion targets in CTC isolation techniques may enhance the sensitivity and specificity of detection, offering a comprehensive approach to understanding tumor dynamics. As research continues to uncover the significance of various adhesion molecules in cancer progression, their integration into CTC technologies will likely enhance the overall efficacy of cancer diagnostics and prognostication. The exploration of these adhesion molecules represents a promising avenue for improving treatment strategies through better understanding of tumor behavior in real time.

By Region

The regional analysis of the circulating tumor cells (CTCs) prognostic technologies market highlights significant variations in market dynamics and growth potential. North America is currently the largest market, accounting for approximately 40% of the global share, driven by a robust healthcare infrastructure, significant investments in cancer research, and high adoption rates of advanced diagnostic technologies. The region is expected to maintain a CAGR of around 18% during the forecast period, fueled by increasing cancer prevalence and the growing focus on personalized medicine. Europe follows closely, accounting for about 30% of the market share, where increasing awareness about early cancer diagnosis and the presence of several key players in the region contribute to its growth.

Asia Pacific is experiencing the fastest growth in the CTC prognostic technologies market, with a projected CAGR of approximately 21% during the forecast period. This growth is attributed to the rising incidence of cancer, improving healthcare facilities, and increasing investments in advanced diagnostic technologies in countries like China and India. The Latin America and Middle East & Africa regions are also witnessing gradual growth, driven by improving healthcare access and the rising burden of cancer. While these regions represent smaller shares of the global market, their increasing focus on cancer research and diagnostics presents opportunities for growth in the coming years.

Opportunities

The circulating tumor cells (CTCs) prognostic technologies market presents numerous opportunities for growth that stakeholders can leverage. One significant opportunity lies in the increasing investment in cancer research and development, which aims to uncover the underlying mechanisms of cancer progression and metastasis. As more funding is allocated to oncology research, there will be a corresponding demand for advanced diagnostic tools, including CTC technologies that can enhance understanding of tumor behavior. Additionally, the growing emphasis on personalized medicine opens avenues for CTC applications, enabling healthcare providers to tailor treatment approaches based on real-time insights into a patient's tumor dynamics. The potential for integrating CTC data with other biomarkers and genomic information also offers opportunities for developing comprehensive diagnostic and prognostic solutions that cater to the evolving needs of precision oncology.

Another area of opportunity lies in the technological advancements within the CTC prognostic technologies market. Innovations in microfluidics, automation, and artificial intelligence are enhancing the efficiency and accuracy of CTC detection and analysis. The development of point-of-care testing devices that utilize CTCs for rapid diagnosis could revolutionize cancer care by facilitating timely treatment decisions. Furthermore, collaborations between technology developers, research institutions, and healthcare providers can foster the development of novel CTC applications, leading to expanded market reach and acceptance. As stakeholders capitalize on these opportunities, the CTC prognostic technologies market is expected to witness robust growth and innovation in the coming years.

Threats

Despite its promising growth, the circulating tumor cells (CTCs) prognostic technologies market faces several threats that could hinder its advancement. One primary threat is the stringent regulatory environment surrounding medical devices and diagnostic technologies, which may delay the approval and commercialization of novel CTC diagnostic products. The high costs associated with research and development, coupled with the challenges of navigating regulatory pathways, can pose significant barriers to market entry for new players. Additionally, the competitive landscape is becoming increasingly crowded, with numerous companies vying for market share. This intense competition may lead to price wars, impacting profit margins and potentially stalling innovation in the sector.

Another significant threat to the market is the potential for skepticism regarding the clinical utility of CTC technologies among healthcare providers. While substantial evidence supports the prognostic value of CTCs, there may still be reluctance in the clinical community regarding their routine use in practice. Additionally, the rapid advancements in alternative diagnostic technologies, such as next-generation sequencing and liquid biopsies targeting different biomarkers, may divert attention and investment away from CTC technologies. As stakeholders navigate these challenges, they must focus on demonstrating the clinical relevance and cost-effectiveness of CTC applications to ensure sustained growth and acceptance in the oncology landscape.

Competitor Outlook

• Epic Sciences
• Veridex LLC
• Menarini Silicon Biosystems
• Clearbridge BioMedics
• AdnaGen AG
• Sysmex Inostics
• Greiner Bio-One International
• Silicon Biosystems
• OncoOne
• Biocept, Inc.
• Advanced Cell Diagnostics
• CellSearch
• Rarecells Diagnostics
• PureTech Health
• MedImmune

The competitive landscape of the circulating tumor cells (CTCs) prognostic technologies market is characterized by the presence of numerous established companies and emerging startups striving to innovate and capture market share. Major players, such as Epic Sciences and Veridex LLC, are leading the way with their advanced CTC detection and analysis technologies. Epic Sciences, in particular, has developed robust platforms for CTC enrichment and characterization, focusing on personalized medicine applications. This strategic focus on tailored cancer therapies has positioned the company as a key player in the market. Moreover, the continuous investment in research and development enables these companies to enhance their product offerings and maintain a competitive edge against new entrants.

Another significant player, Menarini Silicon Biosystems, is recognized for its pioneering technologies in the isolation and analysis of CTCs. The company has developed the DEPArray system, which allows for the precise recovery of CTCs for further examination, thus providing valuable insights into tumor heterogeneity and treatment responses. With a strong emphasis on innovation and technological advancement, Menarini Silicon Biosystems is well-positioned to lead in the CTC prognostic technologies sector. Additionally, companies like Clearbridge BioMedics and Biocept, Inc. are also making noteworthy contributions to the market with their unique diagnostic approaches and proprietary technologies, further enriching the competitive landscape.

As the market for circulating tumor cells continues to evolve, the competitive dynamics will be influenced by ongoing advancements in technology and increasing collaborations between companies, academic institutions, and research organizations. These partnerships are essential for driving innovation and ensuring that emerging technologies can be efficiently translated into clinical applications. Furthermore, as the importance of CTCs in cancer diagnostics and treatment monitoring becomes more widely recognized, these companies will be critical in shaping the future of cancer care through their continued focus on research, development, and strategic partnerships.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 OncoOne
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 MedImmune
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AdnaGen AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 CellSearch
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Veridex LLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Biocept, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Epic Sciences
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 PureTech Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Sysmex Inostics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Silicon Biosystems
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Clearbridge BioMedics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Rarecells Diagnostics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Advanced Cell Diagnostics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Menarini Silicon Biosystems
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Greiner Bio-One International
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Circulating Tumor Cells CTCs Prognostic Technologies Market, By User
    • 6.1.1 Hospitals & Clinics
    • 6.1.2 Research Institutes
    • 6.1.3 Diagnostic Centers
  • 6.2 Circulating Tumor Cells CTCs Prognostic Technologies Market, By Technology
    • 6.2.1 Epithelial Cell Adhesion Molecule (EpCAM)-Based
    • 6.2.2 Size-Based
    • 6.2.3 Density Gradient Separation
    • 6.2.4 Immunocapture
  • 6.3 Circulating Tumor Cells CTCs Prognostic Technologies Market, By Application
    • 6.3.1 Cancer Diagnosis
    • 6.3.2 Treatment Monitoring
    • 6.3.3 Prognostic Evaluation

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Circulating Tumor Cells CTCs Prognostic Technologies Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Circulating Tumor Cells CTCs Prognostic Technologies market is categorized based on

By Application

• Cancer Diagnosis
• Treatment Monitoring
• Prognostic Evaluation

By User

• Hospitals & Clinics
• Research Institutes
• Diagnostic Centers

By Technology

• Epithelial Cell Adhesion Molecule (EpCAM)-Based
• Size-Based
• Density Gradient Separation
• Immunocapture

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Epic Sciences
• Veridex LLC
• Menarini Silicon Biosystems
• Clearbridge BioMedics
• AdnaGen AG
• Sysmex Inostics
• Greiner Bio-One International
• Silicon Biosystems
• OncoOne
• Biocept, Inc.
• Advanced Cell Diagnostics
• CellSearch
• Rarecells Diagnostics
• PureTech Health
• MedImmune